Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Outcomes in KMT2A-r AML and KMT2A-r ALL patients

From: Intensified conditioning containing decitabine versus standard myeloablative conditioning for adult patients with KMT2A-rearranged leukemia: a multicenter retrospective study

Outcomes

KMT2A-r AML (n = 167)

KMT2A-r ALL (n = 48)

Hazard ratio (95% CI)

P

Incidence (95% CI)

Incidence (95% CI)

  

3-year cumulative incidence of relapse

26.8% (19.6–34.6)

27.4% (15.0–41.2)

1.10 (0.58–2.10)

0.706

3-year overall survival

63.0% (55.1–72.1)

72.2% (59.8–87.0)

0.83 (0.44–1.56)

0.560

3-year disease-free survival

61.0% (53.2–69.9)

65.8% (53.1–81.7)

0.95 (0.54–1.68)

0.860

3-year non-relapse mortality

12.2% (7.4–18.2)

6.8% (1.7–16.8)

0.61 (0.18–2.09)

0.370

  1. Abbreviations: KMT2A-r KMT2A-rearranged, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us